TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer
Brief Summary: The median survival at progression after first-line chemotherapy for metastatic gastric cancer is about 2.5 months. There are no data which a possible benefit of second line therapy. for this reason a trial which investigates a possible benefit or chemotherapy compared to best supportive care as second line treatment is urgently necessary.

Irinotecan shows response rates of 20% in the first line therapy with high rates od disease stabilization. There are few trials investigating irinotecan in the second line setting. Response rates of 20% are reported in tis setting. Irinotecan is supplied without costs from the company Pfizer.


Options:
A: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
B: Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): N/A
C: Arm Label: S-1 plus cisplatin; Type: EXPERIMENTAL; Interventions: Drug: s-1 plus cisplatin | Arm Label: 5-Fu plus cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fu plus cisplatin | Intervention Type: DRUG; Name: s-1 plus cisplatin; Assigned to Arm(s): S-1 plus cisplatin | Intervention Type: DRUG; Name: 5-Fu plus cisplatin; Assigned to Arm(s): 5-Fu plus cisplatin
D: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment
Brief Summary: This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.


Options:
A: Intervention Type: DRUG; Name: Gatifloxacin combined regimen; Assigned to Arm(s): N/A
B: Arm Label: HRZE; Type: ACTIVE_COMPARATOR; Interventions: Drug: isoniazid | Arm Label: MRZE; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) | Intervention Type: DRUG; Name: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol); Assigned to Arm(s): MRZE | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): HRZE
C: Arm Label: TMC207; Type: EXPERIMENTAL; Interventions: Drug: TMC207 | Arm Label: TMC207 and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: Pyrazinamide, Drug: TMC207 | Arm Label: PA-824 and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: Pyrazinamide | Arm Label: PA-824 and moxifloxacin and pyrazinamide; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: Moxifloxacin | Arm Label: Rifafour e-275 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifafour | Arm Label: TMC207 and PA-824; Type: EXPERIMENTAL; Interventions: Drug: PA-824, Drug: TMC207 | Intervention Type: DRUG; Name: PA-824; Assigned to Arm(s): PA-824 and moxifloxacin and pyrazinamide, PA-824 and pyrazinamide, TMC207 and PA-824 | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): PA-824 and pyrazinamide, TMC207 and pyrazinamide | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207, TMC207 and PA-824, TMC207 and pyrazinamide | Intervention Type: DRUG; Name: Rifafour; Assigned to Arm(s): Rifafour e-275 mg | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): PA-824 and moxifloxacin and pyrazinamide
D: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment
Brief Summary: This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.


Options:
A: Arm Label: Regimen 1 - 2EHRZ/4HR (control regimen); Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 2 - 2MHRZ/2MHR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Arm Label: Regimen 3 - 2EMRZ/2MR; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin | Intervention Type: DRUG; Name: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin; Assigned to Arm(s): Regimen 1 - 2EHRZ/4HR (control regimen), Regimen 2 - 2MHRZ/2MHR, Regimen 3 - 2EMRZ/2MR
B: Arm Label: Delamanid 100 mg BID + OBR; Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Optimized Background Regimen (OBR), Drug: Placebo | Arm Label: Delamanid 200 mg BID + OBR; Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Optimized Background Regimen (OBR) | Arm Label: Placebo + OBR; Type: PLACEBO_COMPARATOR; Interventions: Drug: Optimized Background Regimen (OBR), Drug: Placebo | Intervention Type: DRUG; Name: Delamanid; Assigned to Arm(s): Delamanid 100 mg BID + OBR, Delamanid 200 mg BID + OBR | Intervention Type: DRUG; Name: Optimized Background Regimen (OBR); Assigned to Arm(s): Delamanid 100 mg BID + OBR, Delamanid 200 mg BID + OBR, Placebo + OBR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Delamanid 100 mg BID + OBR, Placebo + OBR
C: Arm Label: HRZE; Type: ACTIVE_COMPARATOR; Interventions: Drug: isoniazid | Arm Label: MRZE; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) | Intervention Type: DRUG; Name: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol); Assigned to Arm(s): MRZE | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): HRZE
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Pentostatin For the Treatment of High Risk or Refractory Chronic GVHD in Children
Brief Summary: This is a multicenter trial through the Pediatric Blood and Marrow Transplant Consortium.

The Primary hypothesis of this study is that because of its effect as a potent immunosuppressive agent targeting lymphocytes, pentostatin will show a sustained response in pediatric subjects with severe chronic GVHD. Secondary hypotheses include that the infection and toxicity rate of pentostatin in this setting will be acceptable given its lack of severe myelosuppression, and subjects with refractory chronic GVHD will have significant QOL impairment and symptomatology. These may change as subjects are being treated for their chronic GVHD with pentostatin.


Options:
A: Arm Label: ECP Methoxsalen + Standard of Care; Type: EXPERIMENTAL; Interventions: Drug: ECP Methoxsalen, Drug: Standard of Care | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of Care | Intervention Type: DRUG; Name: ECP Methoxsalen; Assigned to Arm(s): ECP Methoxsalen + Standard of Care | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): ECP Methoxsalen + Standard of Care, Standard of Care
B: Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Pentostatin For the Treatment of High Risk or Refractory Chronic GVHD in Children
Brief Summary: This is a multicenter trial through the Pediatric Blood and Marrow Transplant Consortium.

The Primary hypothesis of this study is that because of its effect as a potent immunosuppressive agent targeting lymphocytes, pentostatin will show a sustained response in pediatric subjects with severe chronic GVHD. Secondary hypotheses include that the infection and toxicity rate of pentostatin in this setting will be acceptable given its lack of severe myelosuppression, and subjects with refractory chronic GVHD will have significant QOL impairment and symptomatology. These may change as subjects are being treated for their chronic GVHD with pentostatin.


Options:
A: Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): N/A
C: N/A
D: Intervention Type: DRUG; Name: Methoxsalen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Extracorporeal Photopheresis; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Combined Use of ITN's and Plant-based Insect Repellent Against Malaria in the Amazon
Brief Summary: Insecticide Treated Nets (ITN's) offer good protection against malaria in Africa where the vector mosquitoes feed indoors late at night. However, in other parts of the world like South America, vectors feed earlier in the evening before people go to bed. In such cases it may be necessary to use alternative treatments in the evening to supplement the efficacy of ITN's. This study compares 2 matched groups of households in the Bolivian Amazon. One group will be given ITN's plus a plant-based insect repellent in the evening, the other has ITN's plus a placebo lotion. Households are monitored over a full malaria season to record numbers of malaria cases.


Options:
A: Arm Label: Topical Repellent & LLIN; Type: EXPERIMENTAL; Interventions: Other: Mosquito topical repellent | Arm Label: Long Lasting Insecticidal Nets; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mosquito topical repellent; Assigned to Arm(s): Topical Repellent & LLIN
B: Intervention Type: DEVICE; Name: Insect Repellent plus Insecticide Treated Net; Assigned to Arm(s): N/A
C: Arm Label: 20% deet insect repellent; Type: EXPERIMENTAL; Interventions: Drug: 20% deet insect repellent | Arm Label: lotion without repellent active; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo control | Intervention Type: DRUG; Name: 20% deet insect repellent; Assigned to Arm(s): 20% deet insect repellent | Intervention Type: DRUG; Name: placebo control; Assigned to Arm(s): lotion without repellent active
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo lotion, Other: Army combat uniform | Arm Label: Combo; Type: ACTIVE_COMPARATOR; Interventions: Other: Ultra 30 Insect Repellent Lotion (30% Lipo DEET), Other: Permethrin Factory-Treated Army Combat Uniforms | Arm Label: Permethrin; Type: ACTIVE_COMPARATOR; Interventions: Other: Permethrin Factory-Treated Army Combat Uniforms, Other: Placebo lotion | Arm Label: DEET; Type: ACTIVE_COMPARATOR; Interventions: Other: Ultra 30 Insect Repellent Lotion (30% Lipo DEET), Other: Army combat uniform | Intervention Type: OTHER; Name: Ultra 30 Insect Repellent Lotion (30% Lipo DEET); Assigned to Arm(s): Combo, DEET | Intervention Type: OTHER; Name: Permethrin Factory-Treated Army Combat Uniforms; Assigned to Arm(s): Combo, Permethrin | Intervention Type: OTHER; Name: Placebo lotion; Assigned to Arm(s): Permethrin, Placebo | Intervention Type: OTHER; Name: Army combat uniform; Assigned to Arm(s): DEET, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of Combined Use of ITN's and Plant-based Insect Repellent Against Malaria in the Amazon
Brief Summary: Insecticide Treated Nets (ITN's) offer good protection against malaria in Africa where the vector mosquitoes feed indoors late at night. However, in other parts of the world like South America, vectors feed earlier in the evening before people go to bed. In such cases it may be necessary to use alternative treatments in the evening to supplement the efficacy of ITN's. This study compares 2 matched groups of households in the Bolivian Amazon. One group will be given ITN's plus a plant-based insect repellent in the evening, the other has ITN's plus a placebo lotion. Households are monitored over a full malaria season to record numbers of malaria cases.


Options:
A: Arm Label: Topical Repellent & LLIN; Type: EXPERIMENTAL; Interventions: Other: Mosquito topical repellent | Arm Label: Long Lasting Insecticidal Nets; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mosquito topical repellent; Assigned to Arm(s): Topical Repellent & LLIN
B: Intervention Type: DEVICE; Name: Insect Repellent plus Insecticide Treated Net; Assigned to Arm(s): N/A
C: Arm Label: Mosquito repellent and LLINs group vs. LLINs group only; Type: EXPERIMENTAL; Interventions: Other: Mosquito repellent | Intervention Type: OTHER; Name: Mosquito repellent; Assigned to Arm(s): Mosquito repellent and LLINs group vs. LLINs group only
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: LLIN | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Intervention Type: DEVICE; Name: mosquito coils; Assigned to Arm(s): 3, 4 | Intervention Type: DEVICE; Name: LLIN; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® Inhaler Combination Product 250/50mcg Twice Daily With Salmeterol DISKUS® Inhaler 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by the FDA for use in patients with COPD.


Options:
A: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol, Drug: Fluticasone Propionate/Salmeterol Combination Product | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): Arm 1
C: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
D: Arm Label: Glycopyrronium bromide; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycopyrronium bromide; Assigned to Arm(s): Glycopyrronium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® Inhaler Combination Product 250/50mcg Twice Daily With Salmeterol DISKUS® Inhaler 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by the FDA for use in patients with COPD.


Options:
A: Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol, Drug: Fluticasone Propionate/Salmeterol Combination Product | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): Arm 1
C: Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): N/A
D: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Strategies for Increasing Osteoporosis Screening and Treatment in a Managed Care Organization
Brief Summary: The purpose of this study is to assess the impact of disease management interventions on bone mineral density screening rates and osteoporosis treatment rates in women age 50-64 years at high risk for osteoporosis.


Options:
A: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control
B: Arm Label: Personal contact (PC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Personal contact (PC) | Arm Label: Interactive technology (IT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive technology (IT) | Intervention Type: BEHAVIORAL; Name: Personal contact (PC); Assigned to Arm(s): Personal contact (PC) | Intervention Type: BEHAVIORAL; Name: Interactive technology (IT); Assigned to Arm(s): Interactive technology (IT)
C: Arm Label: Reminder and Outreach Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reminder and Outreach Intervention | Arm Label: Usual Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reminder and Outreach Intervention; Assigned to Arm(s): Reminder and Outreach Intervention
D: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A

Answer: D